Gilead Sciences, Inc. — GILD

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$114.17$141.66B22.715.412.6%8.5%$3.16
280.0%		7.2

Revenue & Net Income

Revenue & Net Income
  Date Revenue Net Income EPS Revenue Change Net Income Change EPS Change
0 2020-12-31 $24.7B $123.0M $0.10 N/A N/A N/A
1 2021-12-31 $27.3B $6.2B $4.96 10.6% 4961.0% 4860.0%
2 2022-12-31 $27.3B $4.6B $3.66 -0.1% -26.2% -26.2%
3 2023-12-31 $27.1B $5.7B $4.54 -0.6% 23.4% 24.0%
4 2024-12-31 $28.8B $480.0M $4.54 6.0% -91.5% 0.0%
5 TTM 2025-03-31 $22.1B $4.7B $4.76 -23.3% 868.8% 4.8%
6 Average -1.5% 1147.1% 972.5%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

GILD Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 Average
Revenue Growth (%) 10.6% -0.1% -0.6% 6.0% -0.0% 3.9% 3.3%
Revenue Analysts (#) 0 0 0 0 0 8 8
EPS Growth (%) 4961.0% -26.2% 23.4% -91.5% 1993.9% 4.9% 1144.2%
EPS Analysts (#) 0 0 0 0 0 9 9

Expenses

Revenue vs Expenses Expenses % of Revenue
Year Revenue ($) Cost of Revenue ($) R&D ($) Sales & Marketing ($) G&A ($) SG&A ($) Facilities / D&A ($)
2021 $27.3B $4.6B $4.6B $5.2B $2.0B
2022 $27.3B $3.6B $5.0B $5.7B $2.1B
2023 $27.1B $3.8B $5.7B $6.1B $2.7B
2024 $28.8B $3.5B $5.9B $6.1B $2.8B
TTM $28.9B $3.4B $5.9B $1.6B $1.0B $6.0B $2.8B
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) SG&A Change (%) Facilities / D&A Change (%)
2022 -0.09 -21.91 8.17 8.14 2.59
2023 -0.60 7.06 14.89 7.35 28.06
2024 6.04 -8.44 3.31 0.02 2.75
TTM 0.38 -1.66 -0.02 -2.10 0.11
No unmapped expenses.

Segment Performance

axis1_GILD_Cell_Therapy_Products_Tecartus.png
axis1_GILD_Cell_Therapy_Products_Total_Cell_Therapy_Product_Sales.png
axis1_GILD_H_I_V_Product_Sales.png
axis1_GILD_H_I_V_Products_Biktarvy.png
axis1_GILD_H_I_V_Products_Descovy.png
axis1_GILD_H_I_V_Products_Genvoya.png
axis1_GILD_H_I_V_Products_Odefsey.png
axis1_GILD_H_I_V_Products_Other_H_I_V.png
axis1_GILD_H_I_V_Products_Symtuza_Revenue_Share.png
axis1_GILD_Liver_Disease.png
axis1_GILD_Liver_Disease_Products_Other_Liver_Disease.png
axis1_GILD_Liver_Disease_Products_Sofosbuvir_Velpatasvir.png
axis1_GILD_Liver_Disease_Products_Vemlidy.png
axis1_GILD_Oncology_Product.png
axis1_GILD_Other_Products_Am_Bisome.png
axis1_GILD_Other_Products_Other.png
axis1_GILD_Other_Products_Total_Other_Product_Sales.png
axis1_GILD_Other_Products_Yescarta.png
axis1_GILD_Product.png
axis1_GILD_Royalty_Contract_And_Other.png
axis1_GILD_Trodelvy.png
axis1_GILD_Veklury.png
SEGMENTS v2025-09-09 · 2025-09-05 14:59 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
Segment 2022 Rev ($B) 2022 OI ($B) 2023 Rev ($B) 2023 OI ($B) 2024 Rev ($B) 2024 OI ($B) TTM Rev ($B) TTM OI ($B) % of Total (TTM)
Product 80.9B 0.00B 80.8B 0.00B 85.8B 0.00B 86.6B 0.00B 42.6%
H I V Product Sales 34.4B 0.00B 36.4B 0.00B 39.2B 0.00B 41.1B 0.00B 20.2%
H I V Products Biktarvy 20.8B 0.00B 23.7B 0.00B 26.8B 0.00B 28.4B 0.00B 14.0%
Oncology Product 4.28B 0.00B 5.86B 0.00B 6.58B 0.00B 6.55B 0.00B 3.2%
Liver Disease 5.60B 0.00B 5.57B 0.00B 6.04B 0.00B 5.94B 0.00B 2.9%
H I V Products Descovy 3.74B 0.00B 3.97B 0.00B 4.22B 0.00B 5.22B 0.00B 2.6%
Cell Therapy Products Total Cell Therapy Product Sales 2.92B 0.00B 3.74B 0.00B 3.95B 0.00B 3.77B 0.00B 1.9%
H I V Products Genvoya 4.81B 0.00B 4.12B 0.00B 3.52B 0.00B 3.19B 0.00B 1.6%
Other Products Yescarta 2.32B 0.00B 3.00B 0.00B 3.14B 0.00B 3.07B 0.00B 1.5%
Trodelvy 1.36B 0.00B 2.12B 0.00B 2.63B 0.00B 2.78B 0.00B 1.4%
Veklury 7.81B 0.00B 4.37B 0.00B 3.60B 0.00B 2.72B 0.00B 1.3%
Liver Disease Products Sofosbuvir Velpatasvir 3.06B 0.00B 3.07B 0.00B 3.19B 0.00B 2.53B 0.00B 1.2%
H I V Products Odefsey 2.94B 0.00B 2.70B 0.00B 2.58B 0.00B 2.45B 0.00B 1.2%
Liver Disease Products Vemlidy 1.69B 0.00B 1.72B 0.00B 1.92B 0.00B 2.01B 0.00B 1.0%
Other Products Total Other Product Sales 1.89B 0.00B 1.72B 0.00B 1.78B 0.00B 1.44B 0.00B 0.7%
Liver Disease Products Other Liver Disease 0.85B 0.00B 0.77B 0.00B 0.93B 0.00B 1.39B 0.00B 0.7%
Other Products Am Bisome 0.99B 0.00B 0.98B 0.00B 1.06B 0.00B 0.97B 0.00B 0.5%
H I V Products Symtuza Revenue Share 1.06B 0.00B 1.06B 0.00B 1.18B 0.00B 0.95B 0.00B 0.5%
H I V Products Other H I V 1.06B 0.00B 0.80B 0.00B 0.87B 0.00B 0.82B 0.00B 0.4%
Cell Therapy Products Tecartus 0.60B 0.00B 0.74B 0.00B 0.81B 0.00B 0.70B 0.00B 0.3%
Other Products Other 0.90B 0.00B 0.73B 0.00B 0.71B 0.00B 0.47B 0.00B 0.2%
Royalty Contract And Other 0.90B 0.00B 0.55B 0.00B 0.43B 0.00B 0.39B 0.00B 0.2%
GILD_Europe_Member_axis2.png
GILD_Rest_Of_World_Member_axis2.png
GILD_U_S_axis2.png

No segment data available for GILD (axis 2).

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $56,434M
1 Cash $7,926M
2 Total Liabilities $37,356M
3 Total Debt $24,952M
4 Total Equity $19,162M
5 Debt to Equity Ratio 1.30

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S Current P/E
$108.50 4.4% Nicks Growth: 2%
Nick's Expected Margin: 15%
FINVIZ Growth: 26%		 Nicks: 8
Finviz: 71		 Nick's: 1.180 4.7 22.8
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$4.76 EPS TTM $37.43 -65.5% $338.55 212.0%
$7.92 EPS 2025 $62.28 -42.6% $563.30 419.2%
$8.48 EPS 2026 $66.68 -38.5% $603.13 455.9%

Implied Growth

Implied Growth
Average Median Std Dev Current Percentile
TTM Forward TTM Forward TTM Forward TTM Forward TTM Forward
Timeframe
1 Year 13.11% 8.60% 13.18% 8.52% 0.28% 0.31% 12.58% 8.44% 3.4% 32.8%
3 Years 13.11% 8.60% 13.18% 8.52% 0.28% 0.31% 12.58% 8.44% 3.4% 32.8%
5 Years 13.11% 8.60% 13.18% 8.52% 0.28% 0.31% 12.58% 8.44% 3.4% 32.8%
10 Years 13.11% 8.60% 13.18% 8.52% 0.28% 0.31% 12.58% 8.44% 3.4% 32.8%

← Back